Page 1

Trinity Biotech Press Release dated May 25 , 2021 Contact : Trinity Biotech plc John Gillard ( 353 ) -1-2769800 Lytham Partners , LLC Joe Diaz ( 1 ) -602-889-9700 E - mail : investorrelations@trinitybiotech.com Trinity Biotech Announces Results for Q1 , 2021 DUBLIN , Ireland ( May 25 , 2021 ) .... Trinity Biotech plc ( Nasdaq : TRIB ) , a leading developer and manufacturer of diagnostic products for the point - of - care and clinical laboratory markets , today announced results for the quarter ended March 31 , 2021 . Quarter 1 Results Total revenues for Q1 , 2021 were $ 25.6m which compares to $ 21.2m in Q1 , 2020 , an increase of 20.9 % and which were broken down as follows : Point - of - Care Clinical Laboratory Total 2020 Quarter 1 2021 Quarter 1 Increase / ( decrease ) US $ ' 000 US $ ' 000 % 3,335 1,888 ( 43.4 % ) 17,842 23,706 32.9 % 21,177 25,594 20.9 % Point - of - Care revenues for Q1 , 2021 decreased from $ 3.3m to $ 1.9m when compared to Q1 , 2020 , a decrease of 43.4 % . This was primarily due to a delay in the issue of HIV rapid test orders from Africa as a result of COVID - 19 . We are seeing evidence of these COVID - 19 driven delays abating and it is expected that Point - of - Care revenues will increase as 2021 progresses . Clinical Laboratory revenues increased from $ 17.8m to $ 23.7m , which represents an increase of 32.9 % compared to Q1 , 2020. This increase was primarily due to strong sales of products within our COVID - 19 related portfolio of products , with our PCR Viral Transport Media products continuing to be the most significant contributor to revenue within that portfolio . This was partially offset by lower revenues in certain aspects of our business that have not yet returned fully to pre - Covid levels . These include lower testing volumes at our Autoimmunity reference laboratory in New York and our Haemoglobins business which continues to be affected by the deferral of Diabetes instrument purchases as healthcare resources remain stretched by the pandemic . Gross profit for Q1 , 2021 increased from $ 9.3m to $ 10.9m when compared to Q1 , 2020 , a 17.6 % increase . The gross margin of 42.6 % for Q1 , 2021 was lower than the 43.8 % achieved in Q1 , 2020 , with the reduction contributed to by sales mix changes and downward pricing pressure on PCR Viral Transport Media and related collection products due to lower demand , with some customers stockpiling supplies in Q4 , 2020 , plus the impact of the roll out of vaccination programs on COVID- 19 testing . Research and Development expenses remained broadly flat at $ 1.4m , whilst primarily cost savings in selling related expenditures resulted in a slight decrease in Selling , General and Administrative ( SG & A ) expenses from $ 6.1m to $ 6.0m when compared to Q1 2020 .